Welcome to our Host Versus Graft Reaction (HVG) evaluation platform. We are dedicated to providing a comprehensive and in-depth immunogenicity assessment for allogeneic cell therapies.
Platform Features and Applications:
• Next-Generation iHuPBMC Platform from InnoModels Technologies: We utilize the next-generation iHuPBMC platform from InnoModels Technologies, which achieves a complete reconstruction of the human immune system. This technology offers us a model that closely mirrors the actual human environment, allowing for a more accurate evaluation of allogeneic cell therapies.
• In-depth Immunogenicity Assessment: With our platform, we can deeply evaluate the immunogenicity of allogeneic cell therapies, understanding how therapeutic cells interact with the host's immune system.
• Assessment of Potential Alloreactivity: Our evaluation platform can also assess the potential alloreactive response of the recipient to therapeutic cells, providing critical data support for your cell therapy research.
Combining advanced technology and thorough research, our Host Versus Graft Reaction (HVG) evaluation platform offers comprehensive support for your cell therapy research and product development. Should you have any questions or require further insights, please don't hesitate to contact us.

Case: The immune system of humanized mice is utilized by using PBMCs to validate the host-versus-graft (HVG) effect of the tested U-Car and CAR-T cells. This approach examines their ability to survive in the patient's body without being attacked by the patient's immune system.

After inoculation of CAR-T cells, human lymphocytes undergo depletion due to the attack by CAR-T cells, resulting in a downward curve. Mouse-derived lymphocytes lose the suppression by human lymphocytes and rebound. However, after inoculation of U-CAR cells, human lymphocytes do not attack U-CAR cells, allowing continued suppression of mouse-derived lymphocytes.